Everyone is handing you an opinion—every market has its bulls' narrative and its bears' bubble talk. Each dashboard here breaks a single thesis into independent, uncontaminated chains of evidence, with every reading traceable back to its source: AI industry, BTC on-chain, gold positioning, A-share tech boards, US Treasury turning points, Congress trading, biotech, cybersecurity, energy transition, emerging tech, venture capital, manufacturing winners. Price tells us what the market is afraid of; data tells us whether that fear is justified.
scroll — twelve dashboards, one at a timeAI leaders got hit across the board on Oct 30: AMD fell 12.0%, Nvidia fell 5.2%, dragged down by Intel's guidance; cloud providers' median capex growth still held at 114.4% year-over-year, no slowdown — it's valuations that fell, not the business. Oracle's credit default swap spread (the cost of insuring against its debt default) remains near historic highs, and financing-chain risk is still spreading from a single vendor to the entire supply chain. Semiconductors' drawdown from the peak narrowed to 22.2% this period; NVDA's P/E ratio climbed back to 25.9x; Oracle (ORCL), the proxy for financing-chain risk, saw its decline widen to −1.0 percentage points, but that doesn't mean real credit risk has eased. Three scores each verify a different thing: whether the industry is deteriorating (87.5/100), whether the price is attractive (55, up this period, pulling further from the lower edge of the panic zone), and whether a turning point has arrived (0/5). Total warning count 4 red, 5 amber; cash flow coverage for major customers is only 1.2x, below the 1.5x healthy threshold — the score and the ledger still don't match. The monetization gap widened to −13.9pp. Next, watch whether the price rebound can narrow the gap between the industry score and the price score.
On-chain (realized-cap slope) and macro (four conditions for the rate-hike paradigm) are scored separately. The on-chain score is +1.00, neutrally bullish, but that strength comes from the past rally, not a bottom signal — the count of positive readings dropped sharply to 2/10 this period, the first break since this accumulation phase began. Of the three conditions, C1 and C3 have been met: C1's streak has held above 73 days, well past the 7-day threshold, and C3's median long-term holder SOPR stays firmly above 1; C2 is still the bottleneck — net inflows over the past 12 days total only about $21.5 million, far short of the $1 billion threshold. Bitcoin's RSI fell to 34.1 on Oct 30, on the weak side; Binance was reportedly hacked for about $6.36 billion, making sidelined capital more cautious and delaying inflows. The long-term holder SOPR's single-day reading fell below 1 to 0.9953 this period, meaning some long-term holders are selling at a loss — next, watch whether this gap narrows on a rebound or widens again as profit-taking momentum resumes.
Price path plus macro tailwinds/headwinds. Peaked at $5,511 → mid-July low of $3,986 → spiked to 4,600 on Aug 18 but failed to hold, spot now —, 52-week range —. This period: gold fell about 3% in a single day on Oct 30, breaking below the mid-July low; the Fed held rates at 3.75%-4% on Oct 28 by a 10-2 vote, with the odds of a December rate hike at ≈70%, — off the prior peak. Global gold ETFs added another 67 tonnes in September to a record high, central banks logged their 23rd straight month of net buying, and structural buying hasn't let up. Next up to watch: China's October PMI on Oct 31 and the US nonfarm payrolls report on Nov 6.
Focused only on the STAR Market, semiconductors, chips, AI, and optical modules: the thesis judges industry logic, the readings judge pricing, and this time the two point in different directions — the thesis still holds steady on reverse confirmation of domestic substitution, while breadth and price both weakened together. The STAR 50 fell 5.48% on Oct 30 to 1,161 points; the year-to-date reading is −13.6%, and the decline hasn't eased. Breadth remains the weakest link: only 3 constituents are above their 200-day moving average today, i.e. 6%, and only 10% are above their 50-day line — the rally is being held up by just a handful of heavyweight stocks. All four price lines turned weaker, with optical modules falling the hardest. The signal that actually matters lies outside participation breadth — domestic substitution is confirming the other way: equipment makers like AMEC and Hwatsing saw revenue growth of roughly 20-30%, Jiangfeng Electronic's net profit doubled, and ACM Research Shanghai's order backlog rose 88% against the trend; Naura's Q3 growth slowed but there's no systematic sign of orders shifting overseas, so the short thesis remains unproven. Semiconductor sales are not triggered — that red line hasn't been touched yet. Price weakness and deteriorating fundamentals are two different things — next, watch whether breadth and price can stabilize together, or whether this support starts to give way too.
Of the 8 turning-point indicators, only labor-market weakening still hasn't caught up. The FOMC held rates steady at 3.75%-4.00% at its Oct 28 meeting; two officials pushed for an immediate hike, so the hawkish dissent hasn't gone away. Long-end yields kept drifting slightly lower: the 30-year yield fell to 5.32%, narrowing its premium over the mid-July high to 23 basis points — this signal, which once led nonfarm payrolls and CPI, is still choppy. The curve didn't flatten along with it this time: the 2-10 year spread widened to 38 basis points and the 3-month-10 year spread widened to 87 basis points, breaking the flattening trend of recent weeks and diverging from the long end's move. Credit spreads (the extra interest companies pay over Treasuries to borrow) kept narrowing: high-yield OAS closed at 318 basis points, but September housing starts plunged 5.2% month-over-month, far below expectations — high rates are still squeezing real demand, not just inflation. The first estimate of Q3 GDP rose to 3.4%, well above the prior 2.2%, while core PCE's annualized monthly rate eased to 2.5% — resilient growth alongside cooling inflation means the tightening path hasn't been repriced, and instead it's bolstering the soft-landing narrative; the 7-year Treasury auction's winning yield fell to 4.894%, down a sharp 19.1 basis points from September, as issuance demand improved. Next, watch the Nov 4 refunding announcement and the Nov 6 jobs report — the labor-data piece still hasn't caught up.
Based on the STOCK Act disclosure ledger: 16,362 trades, 203 members of Congress, 52% of trades are buys, and Big Tech dominates the list — every row links back to the original filing. This period: Rep. Sessions filed a single disclosure on 10/27 selling more than 25 blue-chip stocks including Apple, Amazon, Microsoft, and Google, totaling $1.35 million to $3.24 million; Rep. Lawler had already filed a sale of Google stock on 10/19. Alphabet's Q3 report on 10/28 beat on revenue (cloud revenue doubled), yet the stock plunged more than 12% the next day, wiping out over $500 billion in market value — its biggest single-day drop since going public. Both lawmakers' sale timing happened to dodge this drop — conspicuous, but no evidence points to inside information. The ledger now stands at 16,362 trades, with buys at 52% of the total — the stock-trading ban remains stuck in the Senate, short of the 60-vote threshold, and Congress is in recess until after the 11/3 election. Next, watch how the election results affect the Oklahoma seat, and whether a new batch of concentrated filings follows the Alphabet selloff.
18,601 trials in progress plus 481 BLAs, split into two evidence tracks: the industry track at 34.8 and the market track at 93.3 — the two keep moving apart, with approvals hitting a record high even as first-in-class BLAs haven't budged in a decade. No new industry facts this period, just small updates to the readings: biotech (XBI)'s 3-month gain rose to 1.68% and its 6-month gain rose to 14.64%, while pharma stocks (the pharmaceutical index)'s 3-month gain eased to 20.62%, still the biggest gainer of the three. Eli Lilly's Q3 earnings landed on Oct 29, with revenue of $24.4 billion, up 39% year-over-year, and it raised its full-year revenue guidance midpoint to $91.5 billion — GLP-1 weight-loss drug demand shows no sign of cooling, confirming this thesis. The industry side is a mixed bag: Akeso's ivonescimab beat AstraZeneca's durvalumab regimen in head-to-head data, but Artiva simultaneously discontinued its core pipeline and is evaluating a sale. New U.S. Treasury rules under the COINS Act would add biologic compounds to the list of technologies barred from investment tied to China, a new regulatory variable. The industry track hasn't been pulled along yet — next, watch whether this recovery in the market track spills over into the industry track, rather than just watching the market's own rebound.
12 U.S.-listed and 14 A-share companies lined up on the same ruler, with growth always measured by actual reported YoY. Zscaler's +25.4% versus CrowdStrike's +25.8% — a growth gap of 0.4pp, a valuation gap of 4.2×. This period: A-share cybersecurity stocks sold off hard on 10/27, with Digital Certification falling 8.92% to lead the declines, giving back earlier policy-driven gains; on 10/28 they flipped into an oversold rebound, with NSFOCUS up 6.85% leading gainers — most of the loss was recovered but the gap wasn't fully closed. The sector's median growth is just 1.2%, yet it trades at a 15.3x valuation — the gap widened to 4.2×. CISA added the PHP2Shell high-severity vulnerability (score 9.2) to its known-exploited list, requiring federal agencies to remediate by 10/29 — such news has usually lifted sector sentiment before, but this time A-share cybersecurity stocks sold off first and only recovered the next day via an oversold bounce; the good news didn't translate into a valuation rally right away. Overseas showed the same earnings-versus-share-price divergence: Fortinet's Q3 revenue rose 20.5% YoY, EPS grew 23%, and it raised full-year guidance for the third straight time, yet the stock plunged 20.1% in a single day because services-revenue growth slowed to 13% — the market cared more about margin structure than revenue growth. On 10/29 the sector's oversold rebound reversed into a broad selloff, led down by Sangfor's 13.3% drop — driven by selling-sentiment spillover from overseas tech stocks rather than deteriorating sector fundamentals: Sangfor's nine-month net profit of RMB 576 million is still growing, while Topsec's nine-month loss continued at RMB 485 million. The same day, Sophos and Unit42 retracted their conclusion that PHP2Shell had been "successfully exploited," but CISA's federal remediation deadline still stands. Next, watch the concentrated Q3 disclosures from Qi An Xin, NSFOCUS, and Venustech on 10/30 to see whether earnings can justify the valuations.
One ruler across five value-chain segments: grid equipment and construction at +29.7%, solar manufacturing at −42.5% — a gap of 72.2pp. Electricity CPI is still outrunning headline inflation by 0.7pp — what's being bought is bottleneck rent, not emissions reduction. This period: nuclear stocks' year-to-date loss stands at 57.9%, still the steepest decline among the five segments; European natural gas prices surged 213% YoY, briefly hitting a four-year high on 10/28 before pulling back to €98.11 — winter power-price pressure remains heavy; U.S. natural gas prices, however, stayed low on mild-winter expectations and didn't rise along with Europe's, widening the regional divergence further. Brent crude rebounded to $111.9, up 13.5% for the month, still short of the $116.72 interim high briefly touched on 10/24. GE Vernova's Q3 report on 10/28 showed EPS of $4.81 (versus $1.64 a year earlier), with order backlog rising to $197 billion and full-year guidance raised — real demand for grid equipment has materialized; stripping out related-party transactions, standalone demand for energy-storage orders still holds up on its own, not just propped up by affiliate deals. Next, watch whether Cameco's Q3 report on 10/30 can carry the baton, and whether the anti-dumping and countervailing duties on solar cells from India, Indonesia, and Laos take effect on 11/2.
22 technologies laid out across 8 themes, with 14 rated as transformative. But only three actually carry hard deadlines: post-quantum 2030, the EU AI Act 2027-12-02, and deepfakes, which are already in effect. This period: for the AI chips underpinning agentic output, the real bottleneck has shifted from wafers to TSMC's CoWoS advanced packaging — Nvidia alone has locked up roughly 60% of total 2026 CoWoS allocation, and the supply-demand gap is expected to still leave about 10% unfilled by the end of 2026, with meaningful relief not likely until 2027. The US Treasury's new Outbound Investment Security Program was published in the Federal Register on Oct 26, adding another review gate for investment in agentic AI and frontier technology — a fourth variable beyond the three hard deadlines. New quantitative evidence this period: the IMF measured the scale of AI circular financing for the first time — 14 deals totaling $300 billion in equity investment, $650 billion in debt, and $1.4 trillion in revenue commitments, with no set timeline for delivery. Thematic ETFs' year-to-date performance split further: six tech-theme ETFs closed down on the same day this period, cybersecurity ETF CIBR's year-to-date gain narrowed to 45.89%, and blockchain ETF BLOK led declines with a 12.96% drop over the past month — what's shrinking is valuation, not the themes themselves, and ETFs under the same emerging-tech label are still heading in two different directions. Next up: watch whether this packaging-capacity gap and the scope of the new rules' effective date become clear together, and when the IMF's circular-financing commitments actually get delivered.
Global H1 funding hit $510B — half a year already topping all of last year. But OpenAI and Anthropic alone captured 43%, while North American seed rounds are −27% — the total belongs to the market, the record belongs to fewer than twenty companies. This period: global Q3 funding fell to $159 billion, with AI's share pulling back for a third straight quarter — 80% in Q1, 70% in Q2, 64% this quarter; but mega-round figures point the other way: 68 rounds of $1 billion-plus this year total $429.09 billion, with AI's share at 89.3% — concentration is rising, not falling. OpenAI and Anthropic together still captured 43% of that total — the overall market is cooling while the top tier keeps tightening its grip; secondary markets have been broadly discounting at the same time, opening a clear gap between pricey primary rounds and secondary selling. Next, watch which flips first — overall Q4 funding or mega-round concentration.
Thrive Holdings has rolled up 70+ legacy businesses at a $12B valuation, General Catalyst has set aside $1.5B to build companies from scratch; China's three leading model companies took 30% of the funding — winners get picked by capital before the market ever gets to validate them. This period: secondary markets weakened in tandem — Zhipu (HKEX:2513) fell 8.49% in a single day and MiniMax (HKEX:100) fell 5.60%, giving back gains that had been driven by Anthropic's IPO prospectus; over the same span, Alphabet's Q3 capex hit $51.355 billion (+114%), with free cash flow negative for a second straight quarter (-$9.065 billion) — cloud providers' spending pressure is spilling over into secondary-market pricing of new AI listings. The reported roughly RMB 100 billion funding round for DeepSeek, implying a roughly RMB 500 billion valuation, remains media-sourced and still unconfirmed. Next, watch whether this round moves from rumor to an official announcement.
Every page is a snapshot—the dashboard itself is live. This landing page gives you the current readings and the interpretive framework; click "Open live dashboard" for the full version—every indicator, data table, and historical series.
All twelve dashboards share the same method: break a judgment into independent, uncontaminated chains of evidence, with every reading's source and threshold stated plainly—the conclusion follows the data, not the sentiment.
Price tells us what the market fears; data tells us whether the fear is right.